Published in Medical Letter on the CDC and FDA, January 23rd, 2005
The new formulation of Invarse, which was approved under a 6-month priority FDA review, will reduce pill count for each dose by more than half (from 5 pills to 2, twice-daily) compared to the current formulation of Invirase 200 mg capsules.
The approval was based on data that show similar drug levels are achieved with Invirase 500 mg tablets and Invirase 200...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA